Related Experiment Video

Updated: May 17, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens

Philip E Grgurich1, Jana Hudcova, Yuxiu Lei

  • 1Department of Pharmacy, Lahey Clinic Medical Center, Burlington, MA 01805, USA.

Expert Review of Respiratory Medicine
|November 9, 2012
PubMed

Insights

Ventilator-associated pneumonia (VAP) from multidrug-resistant (MDR) pathogens is a growing threat in ICUs. Effective management and prevention strategies are crucial to combat this serious healthcare-associated infection.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) pathogens represents a significant challenge in intensive care units.
  • The incidence of VAP due to MDR pathogens has seen a notable increase over the past decade.
  • Identifying risk factors is crucial for VAP prevention and management.

Purpose of the Study:

  • To summarize the current understanding of VAP caused by MDR pathogens.
  • To outline key risk factors associated with MDR VAP.
  • To discuss effective management and prevention strategies for MDR VAP.

Main Methods:

  • Literature review of recent studies on VAP and MDR pathogens.
  • Analysis of identified risk factors for MDR VAP.
  • Synthesis of current guidelines for VAP management and prevention.

Main Results:

  • MDR VAP is linked to factors like advanced age, immunosuppression, prior antibiotic use, and prolonged mechanical ventilation.
  • Common MDR pathogens include MRSA and difficult Gram-negative bacteria like Pseudomonas aeruginosa, Acinetobacter baumannii, CRE, and ESBL-producing bacteria.
  • Appropriate antibiotic selection, optimized dosing, and timely de-escalation are key management components.

Conclusions:

  • Multidrug-resistant VAP poses a substantial threat, necessitating targeted interventions.
  • Evidence-based prevention strategies, including multidisciplinary education and collaboration, are essential.
  • Reducing the burden of MDR VAP can decrease healthcare costs and improve patient outcomes.

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...